Sorafenib suppresses hepatitis B virus gene expression via inhibiting JNK pathway

Abstract

Aim: Hepatitis B virus (HBV) infection is a major cause of chronic liver diseases. Sorafenib is a multikinase inhibitor and an approved anti-liver cancer drug. Here we demonstrated the antiviral effect of sorafenib on HBV gene expression.

Methods: To investigate the effect of sorafenib on HBV gene expression, a luciferase assay was performed with × 1.3 Cp-luciferase HBV construct and reverse transcriptase polymerase chain reaction (PCR), real-time PCR, and Western blotting analyses were performed using HepG2 cells derived from hepatocellular carcinoma and Chang liver cells derived from a normal liver tissue.

Results: Sorafenib suppressed HBV gene expression via inhibiting the JNK pathway. In this process, the farnesoid X receptor (FXR), a transcription factor that has been reported to increase HBV replication and gene expression, was under control of the JNK pathway. Notably, JNK activation increased FXR protein levels, not mRNA levels.

Conclusion: Sorafenib suppressed HBV gene expression via inhibiting the JNK pathway, which regulates FXR activity.

Keywords

Sorafenib / hepatitis B virus / JNK / farnesoid X receptor / antiviral effect

References

[1] Kao JH.Global control of hepatitis B virus infection..Lancet Infect Dis2002;2:395-403

[2] Liang TJ.Hepatitis B: the virus and disease..Hepatology2009;49:S13-21 PMCID:PMC2809016

[3] Liu L,Chen C,McNabola A,Wilhelm S,Carter C.Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5..Cancer Res2006;66:11851-8

[4] Borgia G.Treating chronic hepatitis B: today and tomorrow..Curr Med Chem2006;13:2839-55

[5] Gilbert S,Lamontagne A,Bélanger L.The hepatitis B virus core promoter is strongly activated by the liver nuclear receptor fetoprotein transcription factor or by ectopically expressed steroidogenic factor 1..J Virol2000;74:5032-9 PMCID:PMC110855

[6] Nakamura K,Narita M,Koyama Y,Iwaisako K,Uemoto S.Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9..J Hepatol2012;57:1037-43

[7] Srisuttee R,Malilas W,Cho IR,Horio Y.SIRT1 sensitizes hepatocellular carcinoma cells expressing hepatitis B virus X protein to oxidative stress-induced apoptosis..Biochem Biophys Res Commun2012;429:45-50

[8] Li T,Chiang JY.Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/c-jun pathway in human liver cells..Hepatology2006;43:1202-10 PMCID:PMC1526464

[9] Fung J,Seto WK.Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B..J Antimicrob Chemother2011;66:2715-25

[10] Pramoolsinsup C.Management of viral hepatitis B..J Gastroenterol Hepatol2002;17 Suppl:S125-45

[11] Terrault NA.Benefits and risks of combination therapy for hepatitis B..Hepatology2009;49:S122-8

[12] Xie B,Spechler SJ.Sorafenib for treatment of hepatocellular carcinoma: a systematic review..Dig Dis Sci2012;57:1122-9 PMCID:PMC3596114

[13] Karaman MW,Treiber DK,Atteridge CE,Chan KW,Davis MI,Faraoni R,Hunt JP,Milanov ZV,Pallares G,Pritchard S,Zarrinkar PP.A quantitative analysis of kinase inhibitor selectivity..Nat Biotechnol2008;26:127-32

[14] Rahmani M,Crabtree TR,Nguyen TK,Grant S.The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress..Mol Cell Biol2007;27:5499-513 PMCID:PMC1952105

[15] Michaelis M,Löschmann N,Stange E,Nevels M.The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication..Cell Mol Life Sci2011;68:1079-90

[16] Himmelsbach K,Baumert TF,Blum HE.New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication..Gut2009;58:1644-53